Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus (NASDAQ: EOLS) has announced the issuance of inducement grants to newly hired employees. The company's compensation committee approved the grant of 29,763 restricted stock units (RSUs) to 14 non-executive employees under the Evolus' 2023 Inducement Incentive Plan. The RSUs, which were granted in accordance with Nasdaq Listing Rule 5635(c)(4), will begin vesting on March 7, 2025, with 25% vesting annually over four years. The grants are contingent upon continuous employment through each vesting date and are subject to the terms and conditions of both the incentive plan and the respective RSU agreements.
Evolus (NASDAQ: EOLS) reported strong financial results for Q4 and full-year 2024, with record global net revenue of $79.0M in Q4 (+30% YoY) and $266.3M for FY2024 (+32% YoY). The company achieved profitability ahead of schedule, posting Q4 non-GAAP operating income of $6.7M and full-year non-GAAP operating income of $0.3M.
Key highlights include:
- FDA approval of Evolysse™ in February for dynamic facial lines
- Over 15,300 total accounts with 70% reorder rate
- Evolus Rewards program grew 40% to 1.1M consumers
- Cash position of $87.0M as of December 31, 2024
For 2025, Evolus projects revenue of $345-355M (+30-33% growth), with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue. The company aims to reach $700M in revenue by 2028 with non-GAAP operating margins of at least 20%.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its upcoming participation in two major investor conferences in Miami, FL.
The company's management team will engage in fireside chats and investor meetings at:
- The Leerink Partners Global Biopharma Conference - Tuesday, March 11, 2025, at 9:20 AM ET
- The Barclays 27th Annual Global Healthcare Conference - Wednesday, March 12, 2025, at 3:30 PM ET
Both fireside chats will be accessible through the Investor Relations page on Evolus's website, with webcasts remaining available for 90 days following each presentation.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City. The event will feature a fireside chat with David Moatazedi, President and CEO of Evolus, scheduled for Thursday, February 27, 2025, from 9:30 AM to 10:00 AM ET.
The fireside chat will be accessible via live webcast on the Investor Relations page of the Evolus website, with replay availability extending 90 days after the event.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its fourth quarter and year end 2024 financial results announcement for Tuesday, March 4, 2025, after U.S. financial markets close.
The company will host a conference call and live webcast at 4:30 p.m. ET on the same day, featuring management presentations followed by a question-and-answer session. Participants can join via phone by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the live webcast on Evolus's Investor Relations webpage.
After the call, a replay will be available by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13751816. An archived webcast will also be accessible on the company's website.
Evolus (NASDAQ: EOLS) has received FDA approval for Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels representing the first major technological breakthrough in dermal fillers in a decade. The company plans to launch these products in Q2 2025, expanding its addressable market by 78% to approximately $6 billion.
The products utilize innovative Cold-X™ technology designed to better preserve the HA molecule structure for long-lasting results. In clinical trials involving 140 patients, both products demonstrated statistical superiority compared to Restylane®-L. The company aims to achieve at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028.
Two additional products, Evolysse™ Sculpt and Evolysse™ Lips, are planned for launch in 2026 and 2027 respectively. The company also received EU MDR approval for four HA gels under the brand name Estyme®, with European launch planned for second half of 2025.
Evolus (NASDAQ: EOLS) has announced the approval of inducement grants for 34 newly hired non-executive employees. The compensation package includes 26,897 non-qualified stock options and 99,826 restricted stock units (RSUs). The stock options, priced at $13.11 per share, have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year over four years, starting February 7, 2025.
These grants were approved under Evolus' 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards are contingent upon continuous employment through each vesting date.
Evolus announced its preliminary unaudited net revenue for Q4 and full-year 2024, achieving record results. The company reported $79 million in net revenue for Q4 2024, a 30% increase over Q4 2023. For the full year 2024, Evolus reported $266.3 million in net revenue, representing a 32% increase over 2023 and at the top of its guidance range.
The company expects FDA approval within 90 days for its Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, with a U.S. launch planned for Q2 2025, ahead of schedule. Evolus projects 2025 net revenues of $345-$355 million, a 30-33% growth from 2024, with Evolysse™ and Estyme® HA gels contributing 8-10% of total revenue.
Non-GAAP operating expenses for 2025 are expected to be $230-$240 million, with profitability anticipated for the full year. The company continues to see strong performance from its Jeuveau® and Nuceiva® products, with Jeuveau® adding approximately 830 new accounts in Q4 2024 and a 70% reorder rate. The Evolus Rewards program saw a 40% increase in enrollment, ending 2024 with around 1.1 million consumers. As of December 31, 2024, Evolus had $87 million in cash and cash equivalents.
Evolus (NASDAQ: EOLS) has announced the grant of 15,332 restricted stock units (RSUs) to 6 newly hired non-executive employees. The grants were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025. The RSUs will vest at a rate of 25% annually on each anniversary of the vesting commencement date. The grants serve as an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). Recipients must maintain continuous employment to meet vesting requirements.
Evolus (NASDAQ: EOLS) has granted equity incentives to newly hired non-executive employees in November and December 2023. The November Grants include 9,872 stock options priced at $14.29 per share and 16,596 RSUs to 9 employees. The December Grants comprise 6,034 stock options at $12.66 per share and 22,295 RSUs to 11 employees. Both grants were approved under the company's 2023 Inducement Incentive Plan, with vesting dates set for November 7, 2024, and December 7, 2024, respectively. The stock options have a 10-year term with 25% annual vesting over 4 years, while RSUs vest 25% annually.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
